Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group

8 Dec 2014

Abstract excerpt

BACKGROUND: Juvenile myelomonocytic leukemia (JMML) is not durably responsive to chemotherapy, and approximately 50% of patients relapse after hematopoietic stem cell transplant (HSCT). Here we report the activity and acute toxicity of the farnesyl transferase inhibitor tipifarnib, the response rate to 13-cis retinoic acid (CRA) in combination with cytoreductive chemotherapy, and survival following HSCT in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Lymphocytic Leukemia Research
Share to Retinoids in leukemia and cellular processes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25704135
DOI: 10.1002/pbc.25342

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology GroupPMID 25704135Read ↗

Current Treatment of Juvenile Myelomonocytic LeukemiaSemantic proximity Read ↗

A reduced-toxicity myeloablative conditioning approach for hematopoietic cell transplant in juvenile myelomonocytic leukemiaSemantic proximity Read ↗

Diagnosis and treatment of juvenile myelomonocytic leukemiaSemantic proximity Read ↗

Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial.Semantic proximity Read ↗

Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia.Semantic proximity Read ↗

Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemiaSemantic proximity Read ↗

A predictive classifier of poor prognosis in transplanted patients with juvenile myelomonocytic leukemia: a study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.Semantic proximity Read ↗

Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemiaSemantic proximity Read ↗

Targeted therapy in juvenile myelomonocytic leukemia: Where are we now?Semantic proximity Read ↗

Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia: A Report from the Japan Society for Hematopoietic Cell TransplantationSemantic proximity Read ↗

[Juvenile myelomonocytic leukemia (JMML): recent advances in molecular pathogenesis and treatment].Semantic proximity Read ↗

How I treat juvenile myelomonocytic leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.